Asset Management One Co. Ltd. trimmed its stake in Catalent Inc (NYSE:CTLT) by 23.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,827 shares of the company’s stock after selling 5,440 shares during the period. Asset Management One Co. Ltd.’s holdings in Catalent were worth $706,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Acrospire Investment Management LLC lifted its position in shares of Catalent by 72.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after purchasing an additional 1,300 shares during the period. Quantbot Technologies LP increased its stake in Catalent by 110.7% during the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after purchasing an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. bought a new stake in Catalent during the 3rd quarter valued at about $164,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Catalent by 12.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares in the last quarter. Finally, Advisor Group Inc. increased its stake in Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares in the last quarter. 99.37% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research note on Tuesday. First Analysis assumed coverage on shares of Catalent in a research note on Friday, January 5th. They issued an “equal weight” rating for the company. Royal Bank of Canada assumed coverage on shares of Catalent in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $44.44.
In related news, Director Uwe Roehrhoff bought 7,500 shares of the stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
Catalent Inc (CTLT) traded up $0.60 during mid-day trading on Friday, hitting $43.00. 549,834 shares of the stock traded hands, compared to its average volume of 719,530. Catalent Inc has a 1 year low of $25.51 and a 1 year high of $43.39. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. The stock has a market capitalization of $5,633.24, a P/E ratio of 49.43, a PEG ratio of 2.69 and a beta of 1.41.
Catalent (NYSE:CTLT) last released its earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The firm had revenue of $543.90 million for the quarter, compared to the consensus estimate of $490.75 million. During the same quarter in the previous year, the firm earned $0.16 earnings per share. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. equities analysts expect that Catalent Inc will post 1.47 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/asset-management-one-co-ltd-sells-5440-shares-of-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.